We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

BioLineRx's BL-8040 Receives Orphan Drug Designation for Treatment of AML

BL-8040's Phase 2 study results expected towards the end of 2013.
News

Debiopharm and TCGLS Enter Into an Exclusive Research Agreement

Collaboration to develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm.
News

New Muscular Dystrophy Treatment Shows Promise in Early Study

A preclinical study has found that a new oral drug shows early promise for the treatment of muscular dystrophy.
News

Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase

Stem Cell Therapeutics Corp. announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase.
News

Alzheimer’s Missing Link Found: Is a Promising Target for New Drugs

Researchers have discovered a protein that is the missing link in the complicated chain of events that lead to Alzheimer’s disease.
News

Novel Nanoparticles Developed to Deliver Healing Drugs Directly to Bone Cracks

A novel method for delivering healing drugs to newly formed microcracks in bones may help patients with osteoporosis and other medical conditions.
News

Structural Insights into the Functions of the FANCM-FAAP24 Complex in DNA Repair

This study reports the crystal structure of human FANCM-FAAP24 complex, which together with the biological data provide the molecular insights into its functions in DNA repair.
News

Two Pfam Protein Families Characterized by a Crystal Structure of Protein lpg2210

NIH centers are systematically targeting uncharacterized proteins with the goal of providing structural information for a significant portion of the protein universe.
News

D&A PHARMA Presents 3 Major Clinical Studies at the 14th Congress of ESBRA

Company will present the results of several international clinical studies (essentially GATE 1,GATE 2 and GUM) including a population of 2.500 alcohol-dependent patients.
News

Acton Pharmaceuticals, Inc. to be Acquired by Meda for up to $200 Million

Acton Pharmaceuticals, Inc. announced that it has entered into a definitive agreement under which the Company will be acquired by Meda in an all cash transaction.
Advertisement